Search results
Found 10083 matches for
Researchers at the MRC Weatherall Institute of Molecular Medicine have recently discovered why a class of cancer drugs is beneficial only in a subset of patients. The results could pave the way for the future development of these drugs, known as PNP-inhibitors, as personalised medicines.